CombiMatrix and Pathology, Inc. Partner to Market Prenatal Tests

CombiMatrix Corporation CBMX today announced that it has entered into a strategic partnership with Pathology, Inc. whereby Pathology, Inc. will market and distribute CombiMatrix chromosomal microarray tests for the Products of Conception (POC) testing market in designated geographic areas. The POC testing market is a subset of the overall prenatal testing market. The two-year agreement gives Pathology, Inc. the exclusive right to market or distribute the microarray tests on behalf of CombiMatrix in the states of California and Nevada and the St. Louis and Chicago metropolitan areas. Pathology, Inc. is a full-service, independent Women's Health laboratory based in Torrance, California. POC testing allows OB/GYN physicians and other women's health clinicians to better determine if there is a genetic cause behind a miscarriage or multiple events. As in other areas of prenatal genetic analysis, microarray testing is believed by many to be the coming standard of care as it identifies a greater number of possible genetic abnormalities more accurately than traditional methods. "This agreement allows us to better serve the POC market, a very important area of specialty for our physician customers See full press release